Generalizability of SELECT to cardiac surgical patients: analysis of the TRICS III randomized trial
Year: 2025
Type: article
Abstract: Background: The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial reported a 20% reduction in risk of a 3-point major adverse cardiac and cerebrovascular endpoint (MACCE) in nondiabetic patients with established cardiovascular (CV) disease and a body mass index of ≥27 randomized to semaglutide 2.4 mg weekly.1 Previous reports have estimated the prevalence of obesity to be ∼10% in patients undergoing cardiac surgery,2 with a paradoxical protective benefit of overweight and obese phenotypes compared with underweight, normal weight, and morbidly obese patients. A recently published prespecified subanalysis of the SELECT trial demonstrated preserved efficacy of semaglutide in patients following coronary artery bypass grafting (CABG) surgery [HR: 0.72 (0.54-0.95)], with larger absolute risk reductions (ARRs) in patients with vs without a history of CABG (2.3% vs 1.0%).3 Given that patients undergoing cardiac surgery represent a high-risk subset of those with established CV disease, there may be a meaningful proportion that would benefit from treatment with semaglutide.
Source: Figshare
Authors: Nitish K Dhingra (14832449), Raj Verma (13012894), C David Mazer (14832457), Subodh Verma (3398249)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7073981229
FWCI:
Cites:
Cited by:
Related to: